Navigation Links
Auxogyn Completes $20 Million In Series A Funding
Date:2/2/2012

MENLO PARK, Calif., Feb. 2, 2012 /PRNewswire/ -- Auxogyn, Inc., a privately-held company focused on advancing women's reproductive health, today announced the close of the final tranche of its Series A financing, bringing the total funding to $20 million. The initial tranche was placed in May 2010, and investors in the round include Kleiner Perkins Caufield and Byers, TPG Biotech and Merck Serono Ventures.

"Over the course of the last year, we have executed an aggressive operating plan in preparation for the commercialization of our first product, Eeva. Importantly, we expect to announce data from our five-site, 150-patient clinical study in the months ahead that will then be used as part of our regulatory filings in Europe and the United States," said Lissa Goldenstein, president and chief executive officer of Auxogyn.

"In evaluating investments throughout the medical technology field, we were impressed with Auxogyn's unique approach of bringing scientific rigor and data analytics backed by a robust intellectual property portfolio and top-tier clinical advisors to a market in desperate need of improved results," said Mark Gudiksen, Ph.D., principal of TPG Biotech and member of Auxogyn's board of directors.

"As the leader in fertility, Merck Serono is committed to investing in innovative technologies to improve the chance of a successful IVF pregnancy," said Nilesh Kumar Ph.D., director, Merck Serono Ventures. "This investment reflects our confidence in achieving this goal."

"Having developed its first product, initiated a substantive clinical study, and built a sound organizational infrastructure, Auxogyn has set the stage for an exciting 2012, springboarding toward commercialization in the latter half of the year," said Beth Seidenberg, M.D., partner at Kleiner Perkins Caulfield and Byers and a member of the Auxogyn board of directors.

About Eeva™
Auxogyn's non-invasive early embryo viability assessment (Eeva) system may improve IVF outcomes by providing IVF clinicians and patients with objective information on embryo viability.  Eeva's proprietary software automatically analyzes embryo development against scientifically and clinically validated cell-division timing parameters.  With Eeva's quantitative data on each embryos' potential development, IVF clinicians can optimize the treatment path for their patients undergoing IVF procedures.

About Kleiner Perkins Caufield & Byers
Since its founding in 1972, Kleiner Perkins Caufield & Byers has backed entrepreneurs in more than 500 ventures including AOL, Amazon.com, Citrix, Compaq, Electronic Arts, Genentech, Genomic Health, Google, Intuit, Juniper Networks, Netscape, Sun, Symantec, Verisign, WebMD and Zynga. KPCB portfolio companies employ more than 350,000 people worldwide. More than 150 of the firm's portfolio companies have gone public, and many other KPCB ventures have achieved success through mergers and acquisitions. KPCB focuses its global investments in three practice areas - digital, greentech and life sciences - and provides entrepreneurs with company-building expertise out of its offices in Silicon Valley, Beijing and Shanghai.

About TPG Biotech
TPG Biotech is part of the growth equity and venture investment platform of TPG, the global private investment firm.  With more than $1 billion under management, TPG Biotech targets investments in pharmaceutical discovery and development, medical technology, diagnostics, healthcare and pharmaceutical services, life sciences, as well as industrial applications of biotechnology.  TPG Biotech's investments in personalized medicine and genomics have included such companies as Genomic Health, XDx, CardioDx and Veracyte.  Please visit www.tpgbiotech.com.

About Merck Serono Ventures
Merck Serono Ventures is the strategic, corporate venture capital fund of Merck Serono, the division for biopharmaceuticals of Merck KGaA. The fund invests in emerging biotechnology companies with the potential to provide breakthrough medical solutions in Merck Serono's focus therapeutic areas: Oncology, Neurodegenerative Diseases, Rheumatology, Fertility and Endocrinology. In addition, Merck Serono Ventures invests in companies developing innovative technologies that could enable the discovery and development of new products in its core therapeutic areas. For more information, visit www.merckserono.com

About Auxogyn
Auxogyn, Inc. is focused on advancing the field of reproductive health through its uniquely-combined knowledge of early human developmental biology, advanced computer vision technology and best clinical practices. The company's first product, Early Embryo Viability Assessment (Eeva), provides quantitative information regarding embryo development, to assist IVF clinicians in optimizing the treatment path for their patients undergoing IVF procedures.  Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, TPG Biotech and Merck Serono Ventures. For more information regarding Auxogyn please visit www.auxogyn.com.

 

 

 

 


'/>"/>
SOURCE Auxogyn, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Auxogyn Licenses Non-invasive Embryo Assessment Technology From Stanford University
2. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
3. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
4. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
5. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
6. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
7. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
8. China Sky One Medical, Inc. Completes Acquisition of Peng Lai Jin Chuang Company
9. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
10. Roche completes acquisition of ARIUS
11. Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... -- Axovant Sciences Ltd. (NYSE: AXON ), ... of dementia, today announced that data on the investigational ... will be presented at the 2016 Clinical Trials in ... in San Diego . Intepirdine presentations ... complex measures of activities of daily living (ADLs) and ...
(Date:12/5/2016)... -- Research and Markets has announced the addition ... Companies" to their offering. ... , , This report ... technologies such as proteomics and metabolomics. Molecular diagnostics technologies are used ... on biomarker. Currently the most important applications of biomarkers ...
(Date:12/5/2016)... ... December 05, 2016 , ... In anticipation ... and lumbar disc production, company President, Jake Lubinski will be traveling to Germany ... AxioMed disc in Cologne and Karlsruhe to discuss the benefits of a viscoelastic ...
(Date:12/5/2016)... SAN DIEGO , Dec. 5, 2016 /PRNewswire-USNewswire/ ... treatments for congestive heart failure and other chronic ... is joining the company as Chief Financial Officer ... Renova Therapeutics with 20 years of experience in ... closely held biotech and software companies. Most recently, ...
Breaking Biology Technology:
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  higi ... a new partnership initiative targeting national brands, industry ... and reward their respective audiences for taking steps ... Since its inception in 2012, higi has built ... US, impacting over 38 million people who have ...
(Date:11/28/2016)... Nov. 28, 2016 "The ... of 16.79%" The biometric system market is in ... in the near future. The biometric system market is ... 2022, at a CAGR of 16.79% between 2016 and ... of biometric technology in smartphones, rising use of biometric ...
(Date:11/21/2016)...   Neurotechnology , a provider of high-precision ... that the MegaMatcher On Card fingerprint matching algorithm ... NIST Minutiae Interoperability Exchange (MINEX) III ... of the evaluation protocol. The ... fingerprint templates used to establish compliance of template ...
Breaking Biology News(10 mins):